Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GJB2 | P29033 | 7/20 | 0.55 |
| ▸ | GJA1 | P17302 | 5/20 | 0.55 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.39 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.39 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | AGXT | P21549 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | TACR2 | P21452 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL971023 | 1.00 | GJB2 (0.55) | GJB2GJA1SSTR1SSTR2SSTR4 | |
| SCHEMBL12920323 | 1.00 | GJB2 (0.55) | GJB2GJA1SSTR1SSTR2SSTR4 | |
| SCHEMBL5027888 | 0.90 | GJB2 (0.51) | GJB2GJA1SSTR1SSTR2SSTR4 | |
| SCHEMBL5027889 | 0.90 | GJB2 (0.51) | GJB2GJA1SSTR1SSTR2SSTR4 | |
| SCHEMBL26443901 | 0.89 | GJB2 (0.50) | GJB2GJA1SSTR1SSTR2SSTR4 | |
| SCHEMBL15481943 | 0.84 | GJB2 (0.48) | GJB2GJA1SSTR1SSTR2SSTR4 | |
| SCHEMBL16757112 | 0.84 | GJB2 (0.48) | GJB2GJA1SSTR1SSTR2SSTR4 | |
| SCHEMBL12347680 | 0.82 | GJB2 (0.45) | GJB2GJA1IDO1AGXTCA1 | |
| SCHEMBL26443920 | 0.81 | GJB2 (0.46) | GJB2GJA1SSTR1SSTR2SSTR4 | |
| SCHEMBL14747303 | 0.81 | GJB2 (0.47) | GJB2GJA1SSTR1SSTR2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201794-A1 | Disaccharides for drug discovery | ALCHEMIA LIMITED (AU) | 2011-08-18 | — | — | US | disclosed |
| US-7875707-B2 | combinatorial libraries; lipid solubility; solid phase synthesis | ALCHEMIA LIMITED (AU) | 2011-01-25 | — | — | US | disclosed |
| US-20060121530-A1 | Disaccharides for drug discovery | VAST BIOSCIENCE PTY LIMITED (AU) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201794-A1 | Disaccharides for drug discovery | UGCG, STT3A, DDOST | GJB2 4842/4885GJA1 4804/4885SSTR1 968/4885 |
| US-20060121530-A1 | Disaccharides for drug discovery | UGCG, STT3A, DDOST | GJB2 4842/4885GJA1 4804/4885SSTR1 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.